IP Library › Granted Patent US 12,351,647
Granted Patent B2
US 12,351,647 · App. 17/821,937 · Granted Jul 8, 2025

Binding agent and assay for PIVKA

Inventors: Bernhard Eckert (Weilheim, DE); Michael Gerg (Munich, DE); Johann Karl (Peissenberg, DE); Martin Kaufmann (Weilheim, DE); Julia Riedlinger (Ottobrunn, DE); Magdelena Swiatek-de-Lange (Penzberg, DE); Lars Hillringhaus (Koenigsdorf-Schoerain, DE); Klaus Hirzel (Baierbrunn, DE); Marcus-Rene Lisy (Geretsried, DE)
Assignee: Roche Diagnostics Operations, Inc.
C07K16/36G01N33/57438G01N33/86C07K2317/565G01N2333/745
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,647
App. No.
17/821,937
Granted
Jul 8, 2025
Kind
B2
Abstract

The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art. The present disclosure also relates to methods of using the specific binding agents to detect the presence of PIVKA-II.

Claims (43)

1. A method for the production of an antibody, the method comprising:

a) selecting the antibody to be produced, wherein the antibody is selected by:

(i) incubating a candidate antibody with a synthetic peptide of SEQ ID NO:1 and measuring their reactivity;

(ii) incubating the candidate antibody with a synthetic peptide of SEQ ID NO:2 and measuring their reactivity;

(iii) incubating the candidate antibody with a synthetic peptide of SEQ ID NO:3 and measuring their reactivity;

(iv) comparing the reactivity of the candidate antibody with the synthetic peptide of SEQ ID NO:1 and the reactivity of the candidate antibody with the synthetic peptide of SEQ ID NO:2;

(v) comparing the reactivity of the candidate antibody with the synthetic peptide of SEQ ID NO:1 and the reactivity of the candidate antibody with the synthetic peptide of SEQ ID NO:3; and

(vi) selecting the candidate antibody as the antibody of the method if the candidate antibody binds to a synthetic peptide of SEQ ID NO: 1, has at least a 10-fold binding preference for the peptide of SEQ ID NO:1 as compared to a synthetic peptide of SEQ ID NO:2, and binds to a synthetic peptide of SEQ ID NO:3 at least as well as compared to the peptide of SEQ ID NO:1;

b) culturing a host cell comprising one or more vectors, the one or more vectors comprising one or more nucleic acid molecules encoding the antibody, and

c) isolating the antibody produced.

2. The method of claim 1 , wherein the candidate antibody and the selected antibody contain CDRs that comprise the following amino acid sequences or variants thereof, wherein the variants differ in at most one amino acid substitution per CDR:

(i) a CDR 1 comprising the amino acid sequence of SEQ ID NO:10, a CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR3 comprising the amino acid sequence of SEQ ID NO:12 in the light chain variable domain, and a CDR 1 comprising the amino acid sequence of SEQ ID NO:13, a CDR2 comprising the amino acid sequence of SEQ ID NO:14, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15 in the heavy chain variable domain;

(ii) a CDR 1 comprising the amino acid sequence of SEQ ID NO:18, a CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a CDR3 comprising the amino acid sequence of SEQ ID NO:20 in the light chain variable domain, and a CDR 1 comprising the amino acid sequence of SEQ ID NO:21, a CDR2 comprising the amino acid sequence of SEQ ID NO:22, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15 in the heavy chain variable domain;

(iii) a CDR 1 comprising the amino acid sequence of SEQ ID NO:18, a CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR3 comprising the amino acid sequence of SEQ ID NO:20 in the light chain variable domain, and a CDR 1 comprising the amino acid sequence of SEQ ID NO:21, a CDR2 comprising the amino acid sequence of SEQ ID NO:25, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15 in the heavy chain variable domain; or

(iv) a CDR 1 comprising the amino acid sequence of SEQ ID NO:18, a CDR2 comprising the amino acid sequence of SEQ ID NO:11, and a CDR3 comprising the amino acid sequence of SEQ ID NO:28 in the light chain variable domain, and a CDR 1 comprising the amino acid sequence of SEQ ID NO:29, a CDR2 comprising the amino acid sequence of SEQ ID NO:25, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15 in the heavy chain variable domain.

3. The method of claim 2 , wherein the amino acid substitutions are conservative amino acid substitutions.

4. The method of claim 1 , wherein the candidate antibody and the selected antibody contain as light chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:16 and as heavy chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:17.

5. The method of claim 1 , wherein the candidate antibody and the selected antibody contain as light chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:23 and as heavy chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:24.

6. The method of claim 1 , wherein the candidate antibody and the selected antibody contain as light chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:26 and as heavy chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:27.

7. The method of claim 1 , wherein the candidate antibody and the selected antibody contain as light chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:30 and as heavy chain variable domain an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO:31.

8. The method of claim 1 , wherein the one or more vectors independently comprise an expression vector.

9. The method of claim 1 , wherein the host cell is selected from the group consisting of a HeLa, HEK293, H9, Per.C6, Jurkat cells, mouse NIH3T3, NS/0, SP2/0, C127, COS 1, COS 7, CVI, quail QC1-3, mouse L, mouse sarcoma, Bowes melanoma, and Chinese hamster ovary (CHO) cell.

10. The method of claim 1 , wherein the host cell is a bacterium selected from the group consisting of E coli, S typhimurium, Serratia marcescens, Corynebacterium (glutamicum), Pseudomonas (fluorescens), Lactobacillus, Streptomyces, Salmonella and Bacillus subtilis.

11. The method of claim 1 , wherein the isolated antibody is further purified to

(i) greater than 95% by weight;

(ii) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator; or

(iii) to homogeneity by SDS-PAGE under reducing or nonreducing conditions.

12. An antibody prepared according to the method of claim 2 .

13. A method of detecting PIVKA-II in a sample comprising the steps of:

a) contacting the sample with the antibody of claim 12 for a time and under conditions sufficient for the formation of an antibody-PIVKA-II complex; and

b) detecting the presence of the antibody-PIVKA-II complex formed in (a), wherein the presence of the antibody-PIVKA-II complex indicates the presence of PIVKA-II in the sample.

14. The method of claim 13 wherein

step a) further comprises contacting the sample with a second specific binding agent to PIVKA-II, wherein the second specific binding agent is detectably labeled, for a time and under conditions sufficient to form an antibody-PIVKA-II-second specific binding agent complex, wherein

step b) comprises measuring the complex formed in a), thereby detecting PIVKA-II in the sample.

15. The method according to claim 14 , wherein the second specific binding agent is a polyclonal or a monoclonal antibody.

16. The method according to claim 14 , wherein the epitope on PIVKA-II bound by the second specific binding agent is comprised within F1/F2.

17. The method according to claim 14 , wherein the epitope on PIVKA-II bound by the second specific binding agent is comprised within F1.

18. The method according to claim 14 , wherein the epitope on PIVKA-II bound by the second specific binding agent is comprised within the Gla-domain of PIVKA-II.

19. A method of diagnosing hepatocellular carcinoma (HCC) in a patient suspected of having HCC, comprising the steps of:

a) obtaining a sample from the patient;

b) contacting the sample with the antibody of claim 13 and a second specific binding agent to PIVKA-II, wherein the second specific binding agent is detectably labeled, for a time and under conditions sufficient to form an antibody-PIVKA-II-second specific binding agent complex; and

c) measuring the complex formed in (b), thereby measuring the amount of PIVKA-II present in the sample, wherein an amount of PIVKA-II greater than a reference level is indicative of the presence of HCC in the patient.

20. The method of claim 1 , wherein the antibody specifically binds to PIVKA-II.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2022
From: ROCHE DIAGNOSTICS GMBH
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 060922/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2022
From: ECKERT, BERNHARD, DR.; GERG, MICHAEL, DR.; KARL, JOHANN, DR.; HILLRINGHAUS, LARS, DR.; HIRZEL, KLAUS, DR.; KAUFMANN, MARTIN; LISY, MARCUS-RENE, DR.; RIEDLINGER, JULIA, DR.; SWIATEK-DE LANGE, MAGDALENA, DR.
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 061354/0621 →
Priority Claims (1)
EP 17181242 · Jul 13, 2017 · regional
Continuity (3)
Continuation 16740778 · Jan 13, 2020
Continuation PCTEP2018068871 · Jul 12, 2018
Related Publication 20230055005A1 · Feb 23, 2023
References Cited (110)
US 5316757A · Sherry et al. · 1994 [cited by applicant]
US 5342606A · Sherry et al. · 1994 [cited by applicant]
US 5385893A · Kiefer · 1995 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5428139A · Keifer et al. · 1995 [cited by applicant]
US 5428155A · Sherry et al. · 1995 [cited by applicant]
US 5462725A · Keifer et al. · 1995 [cited by applicant]
US 5480990A · Keifer et al. · 1996 [cited by applicant]
US 5582981A · Toole et al. · 1996 [cited by applicant]
US 5739294A · Keifer et al. · 1998 [cited by applicant]
US 5750660A · Keifer et al. · 1998 [cited by applicant]
US 5834456A · Keifer et al. · 1998 [cited by applicant]
US 5877397A · Onberg et al. · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 5969108A · McCafferty et al. · 1999 [cited by applicant]
US 10539559B2 · Yamaguchi et al. · 2020 [cited by applicant]
US 11466098B2 · Eckert · 2022 [cited by examiner]
US 20110111856A1 · White et al. · 2011 [cited by applicant]
US 20140024050A1 · Yoshimura et al. · 2014 [cited by applicant]
JP 2013541936 · 2013 [cited by applicant]
JP 2014035278 · 2014 [cited by applicant]
WO 1994020627A1 · 1994 [cited by applicant]
WO 2012002345A1 · 2012 [cited by applicant]
WO WO2012018476A1 · 2012 [cited by examiner]
WO 2012107419A1 · 2012 [cited by applicant]
Janeway et al., Immunobiology, 3rd edition, Garland Publishing Inc., 1997, pp. 3:1-3:11. [cited by examiner]
Rudikoff et al., Proc Natl Acad Sci USA. Mar. 1982;79(6):1979-83. [cited by examiner]
Edwards et al.,J Mol Biol. Nov. 14, 2003;334(1): 103-18. [cited by examiner]
Llyod et al., Protein Eng Des Sel. Mar. 2009;22(3):159-68. doi: 10.1093/protein/gzn058. Epub Oct. 29, 2008. [cited by examiner]
Goel et al., J Immunol. Dec. 15, 2004; 173(12):7358-67. [cited by examiner]
Kanyavuz et al., Nat Rev Immunol. Jun. 2019;19(6):355-368. doi: 10.1038/S41577-019-0126-7. [cited by examiner]
Lescar, et al. Journal of Biological Chemistry 270.30 (1995): 18067-18076. [cited by examiner]
Stryer, L., Biochemistry, 4th edition, W. H. Freeman and Company, 1995, pp. 18-23. [cited by examiner]
Kipriyanov et al., Mol Biotechnol. Jan. 2004;26(1):39-60. doi: 10.1385/MB:26:1:39. PMID: 14734823. [cited by examiner]
Ulrich et al., J Biol Chem. Jul. 15, 1988;263(20):9697-702. PMID: 3133366. [cited by examiner]
Bae et al., BMC Cancer. Oct. 10, 2011;11:435. doi: 10.1186/1471-2407-11-435. PMID: 21985636. [cited by examiner]
Mitchell et al., Targeting Primary Human Ph+ B-Cell Precursor Leukemia-Engrafted SCIO Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies, Journal of Nuclear Medicine, 2003, pp. 1105-1112, vol. 44. [cited by applicant]
Motohara et al., Detection of Vitamin K Deficiency by Use of an Enzyme-Linked Immunosorbent Assay or Circulating Abnormal Prothrombin, Pediatric Research, 1985, pp. 354-357, vol. 19, No. 4. [cited by applicant]
Naraki et al., v-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-v-carboxy orothrombin, Biochimica et Biophysica Acta, 2002, pp. 287-298, vol. 1586. [cited by applicant]
Nikula et al., A Rapid, Single Vessel Method for Preparation of Clinical Grade Ligand Conjugated Monoclonal Antibodies, Nuclear Medicine and Biology, 1995, pp. 387-390, vol. 22, No. 3. [cited by applicant]
Nikula et al., Alpha-Emitting Bismuth Cyclohexylbenzyl DTPA Constructs of Recombinant Humanized anti-CD33 Antibodies: Pharmacokinetics, Bioactivity, Toxicity and Chemistry, Journal of Nuclear Medicine, 1999, pp. 166-176… [cited by applicant]
Nolte et al., Mirror-design of L-oligonucleotide ligands binding to L-arginine, Nature Biotechnology, 1996, pp. 1116-1119, vol. 14. [cited by applicant]
Owens et al., Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides, Proceedings of the National Academy of Sciences USA, 2001, pp. 1471-1476, vol. 98, No. 4. [cited by applicant]
Pearson et al., “Improved tools for biological sequence comparison”, Proceedings of he National Academy of Sciences USA, 1988, pp. 2444-2448, vol. 85. [cited by applicant]
Plockthun, Antibodies from [cited by applicant]
Reiss et al., A family of binary gene vectors with low inter-transformant variation, Plant Physiology (Life Science Advances), 1994, pp. 143-149, vol. 13. [cited by applicant]
Roselli et al., In Vivo Comparison of CHX-DTPA Ligand Isomers in Athymic Mice Bearing Carcinoma Kemografts, Cancer Biotherapy & Radiopharmaceuticals, 1999, pp. 209-220, vol. 14, No. 3. [cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity; Proc Natl. Acad. Sci. USA, Mar. 1982, vol. 79, No. 6, pp. 1979-1983. [cited by applicant]
Ruegg et al., Improved in Vivo Stability and Tumor Targeting of Bismuth-labeled Antibody, Cancer Research, 1990, pp. 4221-4226, vol. 50. [cited by applicant]
Seeber et al., A Robust High Throughput Platform to Generate Functional Recombinant Monoclonal antibodies Using Rabbit B Cells from Peripheral Blood, PLoS One, 2014, e86184, 14 pp., vol. 9, Issue 2. [cited by applicant]
Settler et al., Novel Orbital Shake Bioreactors for Transient Production of CHO Derived IgGs, Biotechnology Progress, 2007, pp. 1340-1346, vol. 23. [cited by applicant]
Stryer, Biochemistry, 4th edition, W. H. Freeman and Company, 1995, pp. 18-23. [cited by applicant]
Taketa et al., Evaluation of Tumor Markers for the Detection of Hepatocellular Carcinoma in Yangon General Hospital, Myanmar, Acta Medica Okayama, 2002, pp. 317-320, vol. 56, No. 6, Article 7. [cited by applicant]
Tamura et al., Blasticidin S Deaminase Gene (BSD): a New Selection Marker Gene for Transformation of [cited by applicant]
Thompson et al., Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Research, 1994, pp. 46… [cited by applicant]
Toyoda et al., Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: A preliminary report, Cancer Science, 2012, pp. 921-925, vol. 103. [cited by applicant]
Uehara et al., Distribution of the heterogeneity of des-v-carboxyprothrombin in patients with hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2005, pp. 1545-1552, vol. 20, No. 10. [cited by applicant]
Ulrich et al., Vitamin K-dependent carboxylation. A synthetic peptide based upon the gamma-carboxylation recognition site sequence of the prothrombin propeptide is an active substrate for the carboxylase in vitro; J. Bi… [cited by applicant]
Verel et al., Quantitative 89Zr Immuno-PET for In Vivo Scouting of 90Y-Labeled Monoclonal Antibodies in Kenograft-Bearing Nude Mice, Journal of Nuclear Medicine, 2003, pp. 1663-1670, vol. 44. [cited by applicant]
Wurm, Production of recombinant protein therapeutics in cultivated mammalian cells, Nature Biotechnology, 2004, pp. 1393-1398, vol. 22, No. 11. [cited by applicant]
Yamaguchi et al., Development of des-y-carboxy prothrombin (DCP) measuring reagent using the LiBASys clinical analyzer, Clinical Chemistry and Laboratory Medicine, 2008, pp. 411-416, vol. 46, No. 3. [cited by applicant]
Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Research, 1997, pp. 3389-3402, vol. 25, No. 17. [cited by applicant]
Bae et al., Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation; BMC Cancer, 2011; vol. … [cited by applicant]
Bajaj et al., Decarboxylalion of y-Carboxyglulamic Acid Residues in Human Prolhrombin, The Journal of Biological Chemistry, 1982, pp. 3726-3731, vol. 287, No. 7. [cited by applicant]
Baldi el al., Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives, Biotechnology Letters, 2007, pp. 677-684, vol. 29. [cited by applicant]
Baldi, Lucia el al., Transient Gene Expression in Suspension HEK-293 Cells: Application to Large-Scale Protein Production, Biotechnology Progress, 2005, pp. 148-153, vol. 21. [cited by applicant]
Blend et al., Labeling anti-HER2/neu Monoclonal Antibodies with 111 In and 90Y Using a Bifunctional PTPA Chelating Agent, Cancer Biotherapy & Radiopharmaceuticals, 2003, pp. 355-363, vol. 18, No. 3. [cited by applicant]
Borowski et al., Metal and Phospholipid Binding Properties of Partially Carboxylated Human Prothrombin Variants, The Journal of Biological Chemistry, 1985, pp. 9258-9264, vol. 260, No. 16. [cited by applicant]
Borowski et al., Prothrombin Requires Two Sequential Metal-dependent Conformational Transitions to Bind Phospholipid Conformation-Specific Antibodies Directed Against the Phospholipid-Binding Site on Prothrombin, The Jo… [cited by applicant]
Briggs et al., Synthesis of functionalised fluorescent dyes and their coupling to amines and amino acids, Journal of the American Chemical Society, Perkin Trans. 1, 1997, pp. 1051-1058. [cited by applicant]
Browne et al., Selection methods for high-producing mammalian cell lines, Trends in Biotechnology, 2007, pp. 425-432, vol. 25, No. 9. [cited by applicant]
Camera et al., Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111 In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts, Nuclea… [cited by applicant]
Camera et al., Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4, 7, 10-tetraazacyclododecane tetraacetic … [cited by applicant]
Denardo et al., Comparison of 1,4,7, 10-Tetraazacyclododecane-N,N′, N″,N′″-tetraacetic acid (DOTA)-Peptide-Chl6, a Novel Immunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2-[p-(Bromoacetamido)benzyl]-DOTA-Ch… [cited by applicant]
Dodeigne et al., Chemiluminescence as diagnostic tool. A review, Talanta, 2000, pp. 415-439, vol. 51. [cited by applicant]
Dyson et al., Production of soluble mammalian proteins in [cited by applicant]
Edwards et al., The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, GLyS; J Mol Biol., 2003, vol. 334, No. 1, pp. 103-118. [cited by applicant]
Fujiyama et al., Clinical evaluation of plasma abnormal prothrombin (PIVKA-11) in patients with hepatocellular carcinoma, Hepatogastroenterology, 1986, pp. 201-205, Abstract only, vol. 33, No. 5. [cited by applicant]
Girard et al., 100-liter transient transfection, Cytotechnology, 2002, pp. 15-21, vol. 38. [cited by applicant]
Goel et al., Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry n the Humoral Immune Response; The Journal of Immunology;, vol. 173, No. 12, pp. 7358-7367. [cited by applicant]
Goldsmith et al., Studies on a family with combined functional deficiencies of vitamin K-dependent coagulation factors, The Journal of Clinical Investigation, 1982, pp. 1253-1260, vol. 69, No. 6. [cited by applicant]
Hartman et al., Two dominant-acting selectable markers for gene transfer studies in mammalian cells, Proceedings of the National Academy of Sciences USA, 1988, pp. 8047-8051, vol. 85. [cited by applicant]
Henikoff et al., Amino acid substitution matrices from protein blocks, Proceedings of the National Academy of Sciences USA, 1992, pp. 10915-10919, vol. 89. [cited by applicant]
Herrera-Estrella et al., Chimeric genes as dominant selectable markers in plant cells, The EMBO Journal, 1983. pp. 987-995, vol. 2, No. 6. [cited by applicant]
Hnatowich et al., The Preparation of DTPA-Coupled Antibodies Radiolabeled with Metallic Radionuclides: an Improved Method, Journal of Immunological Methods, 1983, pp. 147-157, vol. 65. [cited by applicant]
International Search Report issued Oct. 4, 2018, in Application No. PCT/EP2018/068871. [cited by applicant]
Izard et al., An Improved Method for Labeling Monoclonal Antibodies with Samarium-153: Use of the Bifunctional Chelate 2-(p-Isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic Acid, Bioconjugate Chemistry, 1992,… [cited by applicant]
Janeway et al., The Immune System In Health and Disease, Immuno-biology, 3rd edition, Garland Publishing Inc., 1997, pp. 3:1-3:11. [cited by applicant]
Jayasena, Sumedha D., Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics, Clinical Chemistry, 1999, pp. 1628-1650, vol. 45, No. 9. [cited by applicant]
Kanyavuz et al., Breaking the law: unconventional strategies for antibody diversification; Nat Rev. Immunol., 2019, vol. 19, No. 6, pp. 355-368. [cited by applicant]
Kinukawa et al., Epitope characterization of an anti-PIVKA-11 antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-11, Clinical Biochemistry, 2015, pp. 1120-1125, vol. 48, No. 16-17. [cited by applicant]
Klug et al., All you wanted to know about SELEX, Molecular Biology Reports, 1994, pp. 97-107, vol. 20. [cited by applicant]
Kluβmann et al., Mirror-image RNA that binds 0-adenosine, Nature Biotechnology, 1996, pp. 1112-1115, vol. 14. [cited by applicant]
Kobayashi et al., Evaluation of the in Vivo Biodistribution of Indium-111 and Yttrium-88 labeled Pendrimer-1B4M-DTPA and Its Conjugation with Anti-Tac Monoclonal Antibody, Bioconjugate Chemistry, 1999, pp. 103-111, vol.… [cited by applicant]
Kobayashi et al., Evaluation of the in Vivo Biodistribution of Yttrium-Labeled Isomers of CHX-DTPAConjugated Monoclonal Antibodies, Journal of Nuclear Medicine, 1998, pp. 829-836, vol. 39. [cited by applicant]
Kukis et al., Optimized Conditions for Chelation of Yttrium-90-DOT A Immunoconjugates, Journal of Nuclear Medicine, 1998, pp. 2105-2110, vol. 39. [cited by applicant]
Lee et al., Diagnostic Efficiency of Plasma PIVKA-11 Levels in Hepatocellular Carcinoma, Korean Journal of Clinical Pathology, 1997, pp. 395-404, vol. 17, No. 3. [cited by applicant]
Lee et al., Specific Localization, Gamma Camera Imaging, and Intracellular Trafficking of Radiolabelled Chimeric Anti-GD3 Ganglioside Monoclonal Antibody KM871 in SK-MEL-28 Melanoma Xenografts, Cancer Research, 2001, pp… [cited by applicant]
Liebman et al., Des-y-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma, The New England Journal of Medicine, 1984, pp. 1427-1431, Abstract, vol. 310, No. 22. [cited by applicant]
Lescar et al., Crystal Structure of a Cross-reaction Complex between Fab F9.13.7 and Guinea Fowl Lysozyme*; The Journal of Biological Chemistry, vol. 270, No. 30, 1995, pp. 18067-18076. [cited by applicant]
Lim et al., Combined use of AFP, PIVKA-11, and AFP-L3 as tumor markers enhances diagnostic accuracy or hepatocellular carcinoma in cirrhotic patients, Scandinavian Journal of Gastroenterology, 2015, pp. 344-353, vol. 61… [cited by applicant]
Lloyd et al., Modelling the human immune response: performance of a 10″ human antibody repertoire against a broad panel of therapeutically relevant antigens; Protein Engineering, Design & Selection, Mar. 22, 2009, vol. … [cited by applicant]
Mardirossian et al., The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators, Nuclear Medicine and Biology, 1993, pp. 65-74, vol. 20, No. 1. [cited by applicant]
Marrero et al., Des-Gamma Carboxyprothrombin Can Differentiate Hepatocellular Carcinoma From Nonmalignant Chronic Liver Disease in American Patients, Hepatology, 2003, pp. 1114-1121, vol. 37. [cited by applicant]
Marsh et al., The plC plasmid and phage vectors with versatile cloning sites for recombinant selection DY insertional inactivation, Gene, 1984, pp. 481-485, vol. 32. [cited by applicant]
Matasci et al., Recombinant therapeutic protein production in cultivated mammalian cells: current status and future prospects, Drug Discovery Today: Technologies, 2008, pp. e37-e42, vol. 5, No. 2-3. [cited by applicant]
Meares et al., Macrocyclic chelates of radiometals for diagnosis and therapy, British Journal of Cancer, 1990, DP-21-26, vol. 62, Supp X. [cited by applicant]
Meares et al., Conjugation of Antibodies with Bifunctional Chelating Agents: Isothiocyanate and Bromoacetamide Reagents, Methods of Analysis, and Subsequent Addition of Metal lons, Analytical Biochemistry, 1984, pp. 68-… [cited by applicant]
Miederer et al., Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates, Journal of Nuclear Medicine, 2004, pp. 129-137, vol. 45. [cited by applicant]
Mirzadeh et al., Radiometal Labeling of Immunoproteins: Covalent Linkage of 2-(4-Isothiocyanatobenzyl) diethylenetriaminepentaacetic Acid Ligands to Immunoglobulin, Bioconjugate Chemistry, 1990, pp. 59-65, vol. 1. [cited by applicant]